R G G Russell

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint Bisphosphonates: from bench to bedside
    R Graham G Russell
    The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Headington, Oxford, OX3 7LD, UK
    Ann N Y Acad Sci 1068:367-401. 2006
  2. ncbi request reprint Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy
    R Graham G Russell
    The Oxford University Institute of Musculoskeletal Sciences, The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Headington, Oxford, United Kingdom
    Ann N Y Acad Sci 1117:209-57. 2007
  3. doi request reprint Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
    R G G Russell
    Nuffield Department of Orthopaedic Surgery, Oxford University Institute of Musculoskeletal Sciences The Botnar Research Centre, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, UK
    Osteoporos Int 19:733-59. 2008
  4. ncbi request reprint Bisphosphonates: mode of action and pharmacology
    R Graham G Russell
    Botnar Research Centre, Oxford University Institute of Musculoskeletal Sciences, Oxford, United Kingdom
    Pediatrics 119:S150-62. 2007
  5. ncbi request reprint Bone biology and the pathogenesis of osteoporosis
    R Graham G Russell
    The Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, UK
    Curr Opin Rheumatol 18:S3-10. 2006
  6. ncbi request reprint Ibandronate: pharmacology and preclinical studies
    R G G Russell
    The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Headington, Oxford OX3 7LD, UK
    Bone 38:S7-12. 2006
  7. doi request reprint Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases
    M Pazianas
    The Botnar Research Centre, Oxford University, Oxford, UK
    Osteoporos Int 23:2873-84. 2012
  8. doi request reprint Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase
    James E Dunford
    Structural Genomics Consortium, The Botnar Research Centre, University of Oxford, Oxford, United Kingdom
    J Med Chem 51:2187-95. 2008
  9. pmc The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs
    Kathryn L Kavanagh
    Structural Genomics Consortium, University of Oxford, Oxford OX3 7LD, United Kingdom
    Proc Natl Acad Sci U S A 103:7829-34. 2006
  10. pmc Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis
    Rachel M Locklin
    Institute of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford OX3 7LD, United Kingdom
    Mol Cancer Ther 6:3219-28. 2007

Detail Information

Publications23

  1. ncbi request reprint Bisphosphonates: from bench to bedside
    R Graham G Russell
    The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Headington, Oxford, OX3 7LD, UK
    Ann N Y Acad Sci 1068:367-401. 2006
    ..As a result their full therapeutic potential is gradually being realized...
  2. ncbi request reprint Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy
    R Graham G Russell
    The Oxford University Institute of Musculoskeletal Sciences, The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Headington, Oxford, United Kingdom
    Ann N Y Acad Sci 1117:209-57. 2007
    ..As we approach the 40th anniversary of the discovery of their biological effects, there remain further opportunities for using their properties for medical purposes...
  3. doi request reprint Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
    R G G Russell
    Nuffield Department of Orthopaedic Surgery, Oxford University Institute of Musculoskeletal Sciences The Botnar Research Centre, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, UK
    Osteoporos Int 19:733-59. 2008
    ..There is new knowledge about how they work. The differences that exist among individual BPs in terms of mineral binding and biochemical actions may explain differences in their clinical behavior and effectiveness...
  4. ncbi request reprint Bisphosphonates: mode of action and pharmacology
    R Graham G Russell
    Botnar Research Centre, Oxford University Institute of Musculoskeletal Sciences, Oxford, United Kingdom
    Pediatrics 119:S150-62. 2007
    ..Understanding these may help to explain differences in potency, onset and duration of action, and clinical effectiveness...
  5. ncbi request reprint Bone biology and the pathogenesis of osteoporosis
    R Graham G Russell
    The Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, UK
    Curr Opin Rheumatol 18:S3-10. 2006
    ....
  6. ncbi request reprint Ibandronate: pharmacology and preclinical studies
    R G G Russell
    The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Headington, Oxford OX3 7LD, UK
    Bone 38:S7-12. 2006
    ..The findings from all these studies demonstrate the efficacy and safety of intermittent ibandronate regimens and support the development of such regimens for the clinical management of postmenopausal osteoporosis...
  7. doi request reprint Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases
    M Pazianas
    The Botnar Research Centre, Oxford University, Oxford, UK
    Osteoporos Int 23:2873-84. 2012
    ..We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates...
  8. doi request reprint Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase
    James E Dunford
    Structural Genomics Consortium, The Botnar Research Centre, University of Oxford, Oxford, United Kingdom
    J Med Chem 51:2187-95. 2008
    ..77, p < 0.0001) and the final inhibition of FPPS by N-BPs ( R = 0.74, p < 0.0001) are closely linked to antiresorptive efficacy...
  9. pmc The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs
    Kathryn L Kavanagh
    Structural Genomics Consortium, University of Oxford, Oxford OX3 7LD, United Kingdom
    Proc Natl Acad Sci U S A 103:7829-34. 2006
    ..These experiments reveal the molecular binding characteristics of an important pharmacological target and provide a route for further optimization of these important drugs...
  10. pmc Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis
    Rachel M Locklin
    Institute of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford OX3 7LD, United Kingdom
    Mol Cancer Ther 6:3219-28. 2007
    ....
  11. ncbi request reprint The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding
    Kathryn L Kavanagh
    Structural Genomics Consortium, Botnar Research Centre, University of Oxford, United Kingdom
    J Biol Chem 281:22004-12. 2006
    ..Structural comparisons between members of this enzyme class give deeper insights into conserved features important for catalysis...
  12. doi request reprint Differences between bisphosphonates in binding affinities for hydroxyapatite
    M A Lawson
    Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, The Oxford University Institute of Musculoskeletal Sciences, Oxford, UK
    J Biomed Mater Res B Appl Biomater 92:149-55. 2010
    ..These differences may be exploited in the development of biomaterials and may also partly explain the extent of their relative skeletal retention and persistence of biological effects observed in both animal and clinical studies...
  13. ncbi request reprint Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo
    Claire M Edwards
    Institute of Musculoskeletal Sciences and the Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Center, Oxford, United Kingdom
    Int J Cancer 120:1657-63. 2007
    ..The use of bisphosphonate esters such as Apomine represents a novel therapeutic approach in the treatment of myeloma and, indirectly, the associated bone disease...
  14. ncbi request reprint Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment
    R M Locklin
    Nuffield Department of Orthopaedic Surgery, Institute of Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK
    Leukemia 21:805-12. 2007
    ..Specific agonists of TRAIL death receptors would not be subject to this inhibition and thus may provide an alternative specific antimyeloma therapy...
  15. pmc Regulation of bim in glucocorticoid-mediated osteoblast apoptosis
    B Espina
    The Botnar Research Centre, Oxford Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedic Surgery, Oxford, UK
    J Cell Physiol 215:488-96. 2008
    ..These findings suggest that Bim is a novel regulator of osteoblast apoptosis and may be a therapeutic target...
  16. ncbi request reprint Osteoporosis: pathogenesis and clinical intervention
    G Mueller
    The Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, U K
    Biochem Soc Trans 31:462-4. 2003
    ..The changes in bone lead to osteoporosis and fractures, whereas muscle changes (sarcopenia) contribute to frailty, and changes in cartilage lead to osteoarthritis...
  17. ncbi request reprint Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells
    Anke J Roelofs
    Botnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford, Oxford, United Kingdom
    Int J Cancer 119:1254-61. 2006
    ..In conclusion, our studies demonstrate that selective inhibition of Rab prenylation induces apoptosis, but not S-phase arrest, thus identifying distinct molecular pathways that mediate the antimyeloma effect of nitrogen-containing BPs...
  18. doi request reprint Prolonged osteogenesis from human mesenchymal stem cells implanted in immunodeficient mice by using coralline hydroxyapatite incorporating rhBMP2 microspheres
    Kun Fu
    Botnar Research Centre, Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford, UK
    J Biomed Mater Res A 92:1256-64. 2010
    ..Further research is required to optimize the growth factor delivery system and to understand the underlying cellular and molecular mechanisms involved...
  19. ncbi request reprint Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate
    Mong S Marma
    Department of Chemistry, University of Southern California, Los Angeles, CA 90089 0744, USA
    J Med Chem 50:5967-75. 2007
    ..The alpha-F analogue 7e was 1-2 times as active as 7 in J774 cell viability and Rab11 prenylation inhibition assays...
  20. ncbi request reprint Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing
    Frieder Bauss
    Roche Diagnostics, Pharma Research Penzberg, Nonnenwald 2, D 82377 Penzberg, Germany
    Osteoporos Int 15:423-33. 2004
    ..Collectively, the preclinical studies on ibandronate have provided a sound basis for the design of the convenient regimens currently being examined in clinical trials...
  21. pmc Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase
    Anke J Roelofs
    Bone Research Group, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK
    J Pharmacol Exp Ther 322:228-35. 2007
    ..Thus, these findings demonstrate a novel strategy for enhancing the antitumor effects of lovastatin...
  22. ncbi request reprint Herbert Andre Fleisch, MD
    T John Martin
    J Bone Miner Res 22:1651-3. 2007
  23. pmc Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro
    Zachary J Henneman
    Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, New York 14260, USA
    J Biomed Mater Res A 85:993-1000. 2008
    ..These results demonstrate the importance of the presence of carbonate in mediating the dissolution of CAP, and the possible involvement of bone mineral carbonate in observed differences in bone affinities of BPs in clinical use...